Resmed (RMD) Change in Accured Expenses (2009 - 2026)

Resmed has reported Change in Accured Expenses for 18 years, with the latest figure at $103.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 64.65% year-over-year to $103.9 million; the trailing twelve-month figure through Mar 2026 stood at $171.2 million (up 4.52% YoY), and the FY2025 full-year result was $91.0 million, down 25.49% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $103.9 million, up from $10.6 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $122.0 million in Q2 2024, with the low at -$34.4 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged $25.0 million across 5 years, with a median of $10.6 million in 2025.
• The largest YoY upside for Change in Accured Expenses was 36862.42% in 2024 against a maximum downside of 2399.02% in 2024.
• Resmed's Change in Accured Expenses stood at -$17.3 million in 2022, then tumbled by 99.02% to -$34.4 million in 2023, then soared by 112.28% to $4.2 million in 2024, then surged by 152.25% to $10.6 million in 2025, then jumped by 875.82% to $103.9 million in 2026.
• The last three Change in Accured Expenses figures came in at $103.9 million (Q1 2026), $10.6 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.